Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
Kevin J Curran,Kevin J Curran,Steven P. Margossian,Steven P. Margossian,Nancy A. Kernan,Nancy A. Kernan,Lewis B. Silverman,Lewis B. Silverman,David A. Williams,David A. Williams,Neerav Shukla,Rachel Kobos,Christopher J. Forlenza,Peter G. Steinherz,Peter G. Steinherz,Susan E. Prockop,Susan E. Prockop,Farid Boulad,Farid Boulad,Barbara Spitzer,Barbara Spitzer,Maria Cancio,Maria Cancio,Jaap Jan Boelens,Andrew L. Kung,Yasmin Khakoo,Yasmin Khakoo,Victoria Szenes,Jae H. Park,Craig S. Sauter,Glenn Heller,Xiuyan Wang,Brigitte Senechal,Richard J. O'Reilly,Isabelle Riviere,Michel Sadelain,Renier J. Brentjens +36 more
Reads0
Chats0
TLDR
The data supports the safety of CD19-specific CAR T cell therapy for R/R B-ALL and suggest that dose intensity of conditioning chemotherapy and minimal pre-treatment disease burden have a positive impact on response without a negative effect on toxicity.About:
This article is published in Blood.The article was published on 2019-12-26 and is currently open access. It has received 170 citations till now. The article focuses on the topics: Minimal residual disease & Cyclophosphamide.read more
Citations
More filters
Journal ArticleDOI
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
Alexandre V. Hirayama,Jordan Gauthier,Kevin A. Hay,Kevin A. Hay,Jenna M. Voutsinas,Qian Wu,Ted Gooley,Daniel Li,Sindhu Cherian,Xueyan Chen,Barbara S. Pender,Reed M. Hawkins,Aesha Vakil,Rachel N. Steinmetz,Utkarsh Acharya,Utkarsh Acharya,Ryan D. Cassaday,Ryan D. Cassaday,Aude G. Chapuis,Aude G. Chapuis,Tejaswini Dhawale,Paul C. Hendrie,Hans-Peter Kiem,Hans-Peter Kiem,Ryan C. Lynch,Ryan C. Lynch,J L Ramos,J L Ramos,Mazyar Shadman,Mazyar Shadman,Brian G. Till,Brian G. Till,Stanley R. Riddell,Stanley R. Riddell,David G. Maloney,David G. Maloney,Cameron J. Turtle,Cameron J. Turtle +37 more
TL;DR: Analysis of clinical and treatment characteristics, serum biomarkers, and CAR T-cell manufacturing and pharmacokinetic data showed that a lower pre-lymphodepletion serum lactate dehydrogenase (LDH) level and a favorable cytokine profile, defined as serum day 0 monocyte chemoattractant protein-1 (MCP-1) and peak interleukin-7 (IL-7) concentrations above the median, were associated with better PFS.
Journal ArticleDOI
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.
Nirali N. Shah,Daniel W. Lee,Bonnie Yates,Constance M. Yuan,Haneen Shalabi,Staci Martin,Pamela L. Wolters,Seth M. Steinberg,Eva H. Baker,Cindy Delbrook,Maryalice Stetler-Stevenson,Terry J. Fry,David F. Stroncek,Crystal L. Mackall +13 more
TL;DR: PURPOSECD19 chimeric antigen receptor (CD19-CAR) T cells induce high response rates in children and young adults (CAYAs) with B-cell acute lymphoblastic leukemia (B-ALL) but relapse rates are high as discussed by the authors.
Journal ArticleDOI
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial
Franco Locatelli,Gerhard Zugmaier,Carmelo Rizzari,J. Morris,Bernd Gruhn,Thomas Klingebiel,Rosanna Parasole,Christin Linderkamp,Christian Flotho,Arnaud Petit,Concetta Micalizzi,Noemi Mergen,Abeera Mohammad,William Kormany,Cornelia Eckert,Anja Möricke,Mary Sartor,Ondrej Hrusak,Christina Peters,Vaskar Saha,Luciana Vinti,Arend von Stackelberg +21 more
TL;DR: In this article, the authors evaluated event-free survival in children with high-risk first-relapse B-ALL after a third consolidation course with blinatumomab vs consolidation chemotherapy before allogeneic hematopoietic stem cell transplant.
Journal ArticleDOI
How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.
TL;DR: This discussion will provide a framework for institutions and healthcare providers to formulate their own approach to preventing infections in light of the paucity of data specific to this treatment modality.
Journal ArticleDOI
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
Chelsea C. Pinnix,Jillian R. Gunther,Bouthaina S. Dabaja,Paolo Strati,Penny Fang,Misha Hawkins,Sherry Adkins,Jason R. Westin,Sairah Ahmed,Luis Fayad,Hun Ju Lee,Ranjit Nair,Raphael E Steiner,Swaminathan P. Iyer,M. Alma Rodriguez,Michael Wang,Christopher R. Flowers,Sattva S. Neelapu,Loretta J. Nastoupil +18 more
TL;DR: Despite the poor prognosis associated with requiring BT, RT can be an effective bridging strategy and future studies are necessary to identify strategies that may improve access to CAR T-cell therapy and outcomes.
References
More filters
Journal ArticleDOI
Cancer statistics, 2017
TL;DR: The American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival.
Journal ArticleDOI
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L. Maude,Noelle Frey,Pamela A. Shaw,Richard Aplenc,David M. Barrett,Nancy Bunin,Anne Chew,Vanessa E. Gonzalez,Zhaohui Zheng,Simon F. Lacey,Yolanda D. Mahnke,J. Joseph Melenhorst,Susan R. Rheingold,Angela Shen,David T. Teachey,Bruce L. Levine,Carl H. June,David L. Porter,Stephan A. Grupp +18 more
TL;DR: Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL and was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed.
Journal ArticleDOI
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude,Theodore W. Laetsch,Jochen Buechner,S. Rives,Michael Boyer,Henrique Bittencourt,Peter Bader,Michael R. Verneris,Heather E. Stefanski,G.D. Myers,Muna Qayed,B. De Moerloose,Hidefumi Hiramatsu,Krysta Schlis,Kara L. Davis,Paul L. Martin,Eneida R. Nemecek,Gregory A. Yanik,Christina Peters,André Baruchel,Nicolas Boissel,Francoise Mechinaud,Adriana Balduzzi,Joerg Krueger,Carl H. June,Bruce L. Levine,Patricia A. Wood,Tanya Taran,Mimi Leung,Karen Thudium Mueller,Yiyun Zhang,Kapildeb Sen,David Lebwohl,Michael A. Pulsipher,Stephan A. Grupp +34 more
TL;DR: In this global study of CAR T‐cell therapy, a single infusion of tisagenlecleucel provided durable remission with long‐term persistence in pediatric and young adult patients with relapsed or refractory B‐cell ALL, with transient high‐grade toxic effects.
Journal ArticleDOI
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee,James N. Kochenderfer,Maryalice Stetler-Stevenson,Yongzhi K Cui,Cindy Delbrook,Steven A. Feldman,Terry J. Fry,Rimas J. Orentas,Marianna Sabatino,Nirali N. Shah,Seth M. Steinberg,Dave Stroncek,Nick Tschernia,Constance M. Yuan,Hua Zhang,Ling Zhang,Steven A. Rosenberg,Alan S. Wayne,Crystal L. Mackall +18 more
TL;DR: CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
Journal ArticleDOI
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila,Isabelle Riviere,Xiuyan Wang,Shirley Bartido,Jae H. Park,Kevin J. Curran,Stephen S. Chung,Jolanta Stefanski,Oriana Borquez-Ojeda,Malgorzata Olszewska,Jinrong Qu,Teresa Wasielewska,Qing He,Mitsu Fink,Himaly Shinglot,Maher Youssif,Mark Satter,Yongzeng Wang,James Hosey,Hilda Quintanilla,Elizabeth Halton,Yvette Bernal,Diana C. G. Bouhassira,Maria E. Arcila,Mithat Gonen,Gail J. Roboz,Peter Maslak,Dan Douer,Mark G. Frattini,Sergio Giralt,Michel Sadelain,Renier J. Brentjens +31 more
TL;DR: Diagnostic criteria for a severe cytokine release syndrome (sCRS) is defined and serum C-reactive protein, a readily available laboratory study, can serve as a reliable indicator for the severity of the CRS.
Related Papers (5)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude,Theodore W. Laetsch,Jochen Buechner,S. Rives,Michael Boyer,Henrique Bittencourt,Peter Bader,Michael R. Verneris,Heather E. Stefanski,G.D. Myers,Muna Qayed,B. De Moerloose,Hidefumi Hiramatsu,Krysta Schlis,Kara L. Davis,Paul L. Martin,Eneida R. Nemecek,Gregory A. Yanik,Christina Peters,André Baruchel,Nicolas Boissel,Francoise Mechinaud,Adriana Balduzzi,Joerg Krueger,Carl H. June,Bruce L. Levine,Patricia A. Wood,Tanya Taran,Mimi Leung,Karen Thudium Mueller,Yiyun Zhang,Kapildeb Sen,David Lebwohl,Michael A. Pulsipher,Stephan A. Grupp +34 more
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee,James N. Kochenderfer,Maryalice Stetler-Stevenson,Yongzhi K Cui,Cindy Delbrook,Steven A. Feldman,Terry J. Fry,Rimas J. Orentas,Marianna Sabatino,Nirali N. Shah,Seth M. Steinberg,Dave Stroncek,Nick Tschernia,Constance M. Yuan,Hua Zhang,Ling Zhang,Steven A. Rosenberg,Alan S. Wayne,Crystal L. Mackall +18 more
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L. Maude,Noelle Frey,Pamela A. Shaw,Richard Aplenc,David M. Barrett,Nancy Bunin,Anne Chew,Vanessa E. Gonzalez,Zhaohui Zheng,Simon F. Lacey,Yolanda D. Mahnke,J. Joseph Melenhorst,Susan R. Rheingold,Angela Shen,David T. Teachey,Bruce L. Levine,Carl H. June,David L. Porter,Stephan A. Grupp +18 more
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Cameron J. Turtle,Laïla Aïcha Hanafi,Carolina Berger,Ted Gooley,Sindhu Cherian,Michael Hudecek,Daniel Sommermeyer,Katherine Melville,Barbara S. Pender,Tanya M Budiarto,Emily Robinson,Natalia N Steevens,Colette Chaney,Lorinda Soma,Xueyan Chen,Cecilia Yeung,Brent L. Wood,Daniel Li,Jianhong Cao,Shelly Heimfeld,Michael C. Jensen,Stanley R. Riddell,David G. Maloney +22 more